Kera Capital Partners Inc. Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kera Capital Partners Inc. bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, HoldingsChannel reports. The fund bought 2,336 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000.

Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares in the last quarter. Cooper Financial Group lifted its stake in Jazz Pharmaceuticals by 3.7% during the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 156 shares during the last quarter. Coldstream Capital Management Inc. boosted its holdings in Jazz Pharmaceuticals by 7.7% in the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after purchasing an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its stake in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $121.18 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. The firm’s fifty day moving average price is $122.78 and its 200 day moving average price is $114.67. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,253 shares of company stock worth $1,001,434. Company insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.